503
Views
2
CrossRef citations to date
0
Altmetric
Author's View

Humanizing mice for the identification of novel anticancer lipids targeting iNKT cells

, , , , &
Article: e25475 | Received 15 Jun 2013, Accepted 19 Jun 2013, Published online: 01 Jul 2013

References

  • Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22:817 - 90; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104608; PMID: 15032598
  • Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278:1626 - 9; http://dx.doi.org/10.1126/science.278.5343.1626; PMID: 9374463
  • Exley MA, Nakayama T. NKT-cell-based immunotherapies in clinical trials. Clin Immunol 2011; 140:117 - 8; http://dx.doi.org/10.1016/j.clim.2011.04.015; PMID: 21592864
  • Banchet-Cadeddu A, Hénon E, Dauchez M, Renault JH, Monneaux F, Haudrechy A. The stimulating adventure of KRN 7000. Org Biomol Chem 2011; 9:3080 - 104; http://dx.doi.org/10.1039/c0ob00975j; PMID: 21394364
  • Im JS, Arora P, Bricard G, Molano A, Venkataswamy MM, Baine I, et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 2009; 30:888 - 98; http://dx.doi.org/10.1016/j.immuni.2009.03.022; PMID: 19538930
  • Pellicci DG, Patel O, Kjer-Nielsen L, Pang SS, Sullivan LC, Kyparissoudis K, et al. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 2009; 31:47 - 59; http://dx.doi.org/10.1016/j.immuni.2009.04.018; PMID: 19592275
  • Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Ritter G, et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 2005; 6:819 - 26; http://dx.doi.org/10.1038/ni1225; PMID: 16007090
  • Elewaut D, Shaikh RB, Hammond KJ, De Winter H, Leishman AJ, Sidobre S, et al. NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells. J Exp Med 2003; 197:1623 - 33; http://dx.doi.org/10.1084/jem.20030141; PMID: 12810685
  • Wen X, Rao P, Carreño LJ, Kim S, Lawrenczyk A, Porcelli SA, et al. Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc Natl Acad Sci U S A 2013; 110:2963 - 8; http://dx.doi.org/10.1073/pnas.1300200110; PMID: 23382238
  • Capone M, Cantarella D, Schümann J, Naidenko OV, Garavaglia C, Beermann F, et al. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice. J Immunol 2003; 170:2390 - 8; PMID: 12594262